Prosecution over drug price fixing collapses

Public outcry over US generic drug price hikes.

Among the affected medicines was cycloserine, used as a second-line treatment for multidrugresistant (MDR) and extensively-drug-resistant (XDR) tuberculosis, rights to which were acquired in August, 2015, by Rodelis Therapeutics. Rodelis raised the price for 30-tablet blister packs of cycloserine from US$500 to nearly $11 000, but in the face of nationwide outcry over the move, returned rights ...

Vertical Maximum Price Fixing: In Defense of Albrecht

Fixing the heart: must the brain pay the price?

Coronary artery bypass grafting surgery (CABG) has been persuasively shown to prolong life expectancy in a broad spectrum of patients with severe ischemic heart disease.1 Improvements in the procedure during the past 2 decades have allowed operative mortality rates to fall while disease severity, comorbidity rate, and procedural complexity have increased. In one area, however, evidence of impro...

The distribution of harm in price-fixing cases

Antitrust Scrutiny of Price-Fixing Clauses in Patent Licenses

Patent licenses are frequently subjected to antitrust scrutiny, especially when they contain restrictions beyond simple fixed fees and royalties. Clauses that fix the price at which a product is sold have proven contentious, upheld by the courts in some circumstances and rejected in others. No agreement has yet emerged on how to reconcile court decisions and economic rationale. We study the eff...